{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:45:51Z","timestamp":1787060751565,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Existing guidelines have practical gaps in decision and treatment sequencing for BRCA germline pathogenic variant breast cancers. This paper aims to develop clinical-practice consensus guidelines to address these gaps in the clinical management of BRCA germline pathogenic variants-associated breast cancer in the Asia-Pacific region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An expert panel of 16 medical oncologists, geneticists, and breast cancer surgeons from the Asia-Pacific region arrived at 25 statements. The high level of consensus of statements was considered at \u226575%. A survey of 134 healthcare practitioners, breast cancer surgeons, geneticists, oncologists, molecular biologists\/pathologists explored the real- world practices in the Asia-Pacific region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A consensus was reached for 80% of the statements (20\/25) and aligned with the international guidelines. A significant gap was observed between real-world practices and the recommendations of the steering committee members in discussing contralateral risk reducing mastectomy with the patients as a part of standard practice, considering poly ADP-ribose polymerase inhibitor (PARPi) + immunotherapy for early triple negative breast cancer (eTNBC) patients with BRCA variants who don\u2019t achieve pathological complete response after neoadjuvant chemotherapy + immunotherapy, use of adjuvant PARPi in patients with BRCA germline pathogenic variants in eTNBC who have achieved pathological complete response from neoadjuvant therapy, and preference for endocrine therapy + PARPi over endocrine therapy + cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) as escalated adjuvant treatment for BRCA pathogenic variants with high-risk hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2-negative) early breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Testing for BRCA germline pathogenic variants should be expanded to include all young patients with breast cancer. Patients with BRCA germline pathogenic variants should undergo genetic testing before surgery as it can impact surgical intervention decisions and further systemic treatment. The use of neoadjuvant platinum agents in chemotherapy increases the pathological complete response rate. Adjuvant PARPi is preferred over CDK4\/6i as escalated treatment in patients who are HR+\/HER2-negative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1507840","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T01:21:01Z","timestamp":1750641661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management"],"prefix":"10.3389","volume":"15","author":[{"given":"Yeon Hee","family":"Park","sequence":"first","affiliation":[{"name":"Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology, National University Cancer Institute","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Comprehensive Cancer Centre, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Campus Vall Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Alexandra","family":"Dent","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Centre Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique Kiak-Mien","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Ayu","family":"Mulansari","sequence":"additional","affiliation":[{"name":"Haematology-Medical Oncology Division, Internal Medicine Department, Cipto Mangunkusumo National General Hospital\/Universitas Indonesia","place":["Jakarta, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura Md.","family":"Yusof","sequence":"additional","affiliation":[{"name":"Picaso Cancer Centre, Hospital Picaso, Petaling Jaya","place":["Selangor, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances Victoria F.","family":"Que","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, St Luke\u2019s Medical Center, Quezon City and Global City","place":["Metro Manila, Philippines"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napa","family":"Parinyanitikul","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, King Chulalongkorn Memorial Hospital","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cam Phuong","family":"Pham","sequence":"additional","affiliation":[{"name":"The Nuclear Medicine and Oncology Center, Bachmai Hospital","place":["Hanoi, Vietnam"]},{"name":"Nuclear Medicine Department, Hanoi Medical University","place":["Hanoi, Vietnam"]},{"name":"Oncology and Nuclear Medicine Department, University of Medicine and Pharmacy, Vietnam National University","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Aishah","family":"Taib","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, University Malaya, UM Cancer Research Institute","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Genetic Counselling Clinic, National Cancer Center","place":["Goyang, Gyeonggi-do, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoland","family":"Antill","sequence":"additional","affiliation":[{"name":"Familial Cancer Centre, Royal Melbourne Hospital","place":["Melbourne, VIC, Australia"]},{"name":"Faculty of Medicine and Health Sciences, Monash University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00687-1","article-title":"Systemic therapy for early-stage breast cancer: learning from the past to build the future","volume":"19","author":"Agostinetto","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.553080","article-title":"Surgical and systemic treatment of hereditary breast cancer: A mini-review with a focus on BRCA1 and BRCA2 mutations","volume":"10","author":"Pouptsis","year":"2020","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-019-5950-4","article-title":"Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case\u2013control study","volume":"19","author":"Zayas-Villanueva","year":"2019","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2020.04.07","article-title":"Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients","volume":"54","author":"Kim","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic` testing for hereditary breast cancer from the american society of breast surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.12.009","article-title":"Unmet challenges in systemic therapy for early stage breast cancer","volume":"62","author":"Burstein","year":"2022","journal-title":"Breast"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081898","article-title":"Definition of high-risk early hormone-positive HER2-negative breast cancer: A consensus review","volume":"14","author":"Garutti","year":"2022","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v13.i3.209","article-title":"Breast cancer in India: Present scenario and the challenges ahead","volume":"13","author":"Mehrotra","year":"2022","journal-title":"World J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","article-title":"PARP inhibition in breast cancer: progress made and future hopes","volume":"8","author":"Tung","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B15","unstructured":"Breast cancer risk reduction (version 1.2023)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: american society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12935-021-02194-2","article-title":"Contralateral risk-reducing local therapy in breast cancer patients with BRCA1\/2 mutations: systemic review and meta-analysis","volume":"21","author":"Jia","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.02.019","article-title":"Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis","volume":"48","author":"Wang","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012464.pub2","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12529-021-09984-y","article-title":"Decision-making for risk-reducing salpingo-oophorectomy (RRSO) in southeast asian BRCA mutation carriers with breast cancer: A qualitative study","volume":"29","author":"Sa\u2019at","year":"2022","journal-title":"Int J Behav Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01138","article-title":"Managing menopausal symptoms and associated clinical issues in breast cancer survivors","volume":"102","author":"Santen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.474","article-title":"Translating the role of PARP inhibitors in triple-negative breast cancer","volume":"6","author":"Beniey","year":"2019","journal-title":"Oncoscience"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.770663","article-title":"Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: A narrative review","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0529","article-title":"Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis","volume":"19","author":"Li","year":"2022","journal-title":"Cancer Biol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000530584","article-title":"St. Gallen\/vienna 2023: optimization of treatment for patients with primary breast cancer - A brief summary of the consensus discussion","volume":"18","author":"Balic","year":"2023","journal-title":"Breast Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081137","article-title":"Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: development of GRADE (Grades of recommendation, assessment, development and evaluation) recommendation by the italian association of medical oncology (AIOM)","volume":"11","author":"Dieci","year":"2019","journal-title":"Cancers"},{"key":"B29","unstructured":"Jankowitz\n              RC\n            \n            \n              Shah\n              A\n            \n          \n          Neoadjuvant\/adjuvant treatment for breast cancer with SABCS updates\n          \n          2023"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO\u2013ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"key":"B31","unstructured":"Breast cancer (version 5.2020)\n          \n          2020"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(23)04149-2","article-title":"LBA18 - Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12885-016-2500-1","article-title":"Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II\/III breast cancer patients: breast cancer subtype analyses","volume":"16","author":"Yang","year":"2016","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.816642","article-title":"Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications","volume":"13","author":"Wanderley","year":"2022","journal-title":"Front Immunol"},{"key":"B38","unstructured":"Adjuvant olaparib for high-risk, early breast cancer in BRCA1\/2 pathogenic or likely pathogenic variant carriers: Implications for clinical practice\n          \n          2022"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041524","article-title":"Current treatment landscape for early triple-negative breast cancer (TNBC)","volume":"12","author":"Lee","year":"2023","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01711-y","article-title":"Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients","volume":"126","author":"De Boo","year":"2022","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B45","doi-asserted-by":"publisher","first-page":"8753","DOI":"10.1038\/s41598-020-63033-4","article-title":"Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis","volume":"10","author":"Im","year":"2020","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01488-0","article-title":"PARP inhibitors in breast cancer: a short communication","volume":"26","author":"Daly","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.07.012","article-title":"Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer","volume":"65","author":"Viansone","year":"2022","journal-title":"Breast"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1807980","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:30:55Z","timestamp":1773070255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":50,"alternative-id":["10.3389\/fonc.2025.1507840"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1507840","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"article-number":"1507840"}}